Showing results (21-30 of 38) with videos related to
Sort By:
Pageof 4
American Journal of Nephrology|September 14, 2023
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc AnalysisDaisuke Koya, Stefan D Anker, Luis M Ruilope, et al.Diabetes, Obesity & Metabolism|October 4, 2022
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist usePeter Rossing, Rajiv Agarwal, Stefan D Anker, et al.Journal of the American College of Cardiology|May 20, 2021
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 DiabetesGerasimos Filippatos, George L Bakris, Bertram Pitt, et al.Kidney International|November 11, 2022
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetesGeorge L Bakris, Luis M Ruilope, Stefan D Anker, et al.Journal of Hypertension|December 30, 2022
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetesRajiv Agarwal, Luis M Ruilope, Gema Ruiz-Hurtado, et al.JAMA Cardiology|June 14, 2023
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With FinerenoneRajiv Agarwal, Bertram Pitt, Peter Rossing, et al.Diabetes Care|January 21, 2022
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD StudyPeter Rossing, Ellen Burgess, Rajiv Agarwal, et al.Diabetes Care|August 16, 2022
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY AnalysisPeter Rossing, Stefan D Anker, Gerasimos Filippatos, et al.Kidney International Reports|January 10, 2022
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor TherapyPeter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.Diabetes, Obesity & Metabolism|February 1, 2023
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baselineJanet B McGill, Rajiv Agarwal, Stefan D Anker, et al.Pageof 4